SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

 

 

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(AMENDMENT NO. 3)

 

 

Janux Therapeutics, Inc.

(Name of Issuer)

Common Stock

(Title of Class of Securities)

47103J 105

(CUSIP Number)

September 30, 2024

(Date of Event Which Requires Filing of this Statement)

 

 

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

☐ Rule 13d-1(b)

☐ Rule 13d-1(c)

☒ Rule 13d-1(d)

 

*

The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

 

 

 

CUSIP No. 47103J 105    13G    Page 2 of 4 Pages

 

 1.   

 Names of Reporting Persons

 

 David Campbell, Ph.D.

 2.  

 Check the Appropriate Box if a Member of a Group (see instructions)

 (a) ☐  (b) ☐

 

 3.  

 SEC USE ONLY

 

 4.  

 Citizenship or Place of Organization

 

 United States

Number of

Shares

Beneficially 

Owned by

Each

Reporting

Person

With:

    5.    

 Sole Voting Power

 

 2,644,622

   6.   

 Shared Voting Power

 

 0

   7.   

 Sole Dispositive Power

 

 2,644,622

   8.   

 Shared Dispositive Power

 

 0

 9.   

 Aggregate Amount Beneficially Owned by Each Reporting Person

 

 2,644,622(1)

10.  

 Check if the Aggregate Amount in Row (9) Excludes Certain Shares (see instructions)

 

 ☐

11.  

 Percent of Class Represented by Amount in Row 9

 

 4.8%(2)

12.  

 Type of Reporting Person (see instructions)

 

 IN

 

(1)

Includes 2,337,568 shares of common stock issuable within 60 days of September 30, 2024 upon the exercise of stock options held by the Reporting Person.

(2)

The percentage is calculated based on 52,338,762 shares of Common Stock outstanding as of September 30, 2024.

CUSIP No. 47103J 105    13G    Page 3 of 4 Pages

 

Item 1(a).

Name of Issuer:

Janux Therapeutics, Inc., a Delaware corporation

 

Item 1(b).

Address of Issuer’s Principal Executive Offices:

10955 Vista Sorrento Parkway, Suite 200

San Diego, CA 92130

 

Item 2(a).

Name of Person Filing:

David Campbell, Ph.D.

 

Item 2(b).

Address of Principal Business Office or, if none, Residence:

10955 Vista Sorrento Parkway, Suite 200

San Diego, CA 92130

 

Item 2(c).

Citizenship:

USA

 

Item 2(d).

Title of Class of Securities:

Common Stock

 

Item 2(e).

CUSIP Number:

47103J 10 5

 

Item 3.

Not applicable

 

Item 4.

Ownership

 

  (a)

Amount Beneficially Owned: 2,644,622 shares of Common Stock

 

  (b)

Percent of Class: 4.8%

 

  (c)

Number of shares as to which the person has:

 

  (i)

Sole power to vote or to direct the vote: 2,644,622

 

  (ii)

Shared power to vote or to direct the vote: 0

 

  (iii)

Sole power to dispose or to direct the disposition of: 2,644,622

 

  (iv)

Shared power to dispose or to direct the disposition of: 0

 

Item 5.

Ownership of Five Percent or Less of a Class

If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following ☒.

 

Item 6.

Ownership of More than Five Percent on Behalf of Another Person

Not applicable

 

Item 7.

Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person.

Not applicable

CUSIP No. 47103J 105    13G    Page 4 of 4 Pages

 

Item 8.

Identification and Classification of Members of the Group

Not applicable

 

Item 9.

Notice of Dissolution of a Group

Not applicable

 

Item 10.

Certification

Not applicable

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

 

November 14, 2024
Date
/s/ David Campbell
Signature
David Campbell, Ph.D.
Name/Title

The original statement shall be signed by each person on whose behalf the statement is filed or his authorized representative. If the statement is signed on behalf of a person by his authorized representative other than an executive officer or general partner of the filing person, evidence of the representative’s authority to sign on behalf of such person shall be filed with the statement, provided, however, that a power of attorney for this purpose which is already on file with the Commission may be incorporated by reference. The name and any title of each person who signs the statement shall be typed or printed beneath his signature.

Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See Rule 13d-7 for other parties for whom copies are to be sent.

 

Attention:

Intentional misstatements or omissions of fact constitute Federal criminal violations (See 18 U.S.C. 1001)

Janux Therapeutics (NASDAQ:JANX)
Gráfico Histórico do Ativo
De Nov 2024 até Dez 2024 Click aqui para mais gráficos Janux Therapeutics.
Janux Therapeutics (NASDAQ:JANX)
Gráfico Histórico do Ativo
De Dez 2023 até Dez 2024 Click aqui para mais gráficos Janux Therapeutics.